Skip to main content
Premium Trial:

Request an Annual Quote

Amid Tough Market Conditions, Bruker and CombiMatrix Stocks Had Strong February

NEW YORK (GenomeWeb News) – Shares of Bruker and CombiMatrix were among the best performers in February among the stocks tracked by GenomeWeb Daily News (see below), as they bucked a downward trend in the general stock market.
 
The top three performers for the month among the 36 firms that comprise the GWDN Index were Nanogen (+46.3 percent), Bruker (+33.4 percent), and CombiMatrix (+31.3 percent). The bottom three laggards were Nanosphere (-23 percent), Helicos Biosciences (-16 percent), and Sequenom (-15.7 percent).
 
After its shares had dropped nearly 23 percent in January, Bruker’s stock rebounded in February. The firm completed its $1.1 billion acquisition of Bruker BioSpin late in the month. It started March with the introduction of several new mass spectrometry and NMR products at Pittcon 2008, held last week in New Orleans.
 
CombiMatrix’s shares rose steadily throughout the month. In mid-February it announced that it was awarded $31.4 million by the US District Court for the Central District of California in a suit filed against an insurer. Last week, it revised the award upward to $32.1 million.
 
Nanosphere’s shares declined steadily during the month, in advance of its fourth-quarter and fiscal 2007 results, which were announced on Feb. 28. The firm reported that its fourth-quarter revenues dipped slightly while its net loss jumped 56 percent on higher SG&A costs. Nanosphere completed its IPO in November.
 
Helicos, which was among the top three gainers in the Index for January, dropped 16 percent. The firm’s shares have tended to shift significantly on relatively low trading volume compared to many of the other stocks covered by GWDN. Helicos has been publicly traded for less than a year.
 
Early in February, the firm announced that it had taken the first order for its next-generation sequencing platform, and last week disclosed that that first customer is genomic services provider Expression Analysis.
 
Shares of Sequenom also fell during the month in advance of its fourth-quarter and fiscal 2007 financial results, which were released on Feb. 20. While the firm’s Q4 revenues rose 41 percent, its net loss widened 28.3 percent on an increase in expenses.
 
Overall, the GWDN Index was up 1.7 percent for the month of February. In comparison, the Dow Jones Industrial Average lost 3 percent during the month, the Nasdaq slumped 5 percent, and the Nasdaq Biotech Index fell 2.6 percent.
 
While GenomeWeb Daily News covers many more firms than are in the Index, those that have been included have a significant portion of their business focused on molecular biology and cellular research tools and are publicly traded in the US.
 
 
GenomeWeb Daily News Index
Company
Ticker
Current Price
(February
29, 2008)
Last
Price
(January 31, 2008)
% change
Accelrys
ACCL
5.79
6.48
-10.65
Accelr8
AXK
4.20
4.13
1.69
Affymetrix
AFFX
19.18
20.06
-4.39
Agilent
A
30.61
33.86
-9.60
Applied Biosystems
ABI
33.71
31.46
7.15
Beckman
BEC
67.50
66.45
1.58
Becton Dickinson
BDX
90.42
86.44
4.60
Bio-Rad
BIO
94.44
94.79
-0.37
Bruker
BRKR
13.67
10.25
33.37
Caliper
CALP
4.17
4.44
-6.08
Celera
CRA
13.86
15.32
-9.53
Cepheid
CPHD
27.68
30.54
-9.36
Clinical Data
CLDA
20.38
20.97
-2.81
CombiMatrix
CBMX
10.61
8.08
31.31
Compugen
CGEN
2.47
2.75
-10.18
DeCode Genetics
DCGN
2.94
3.44
-14.53
Genomic Health
GHCX
19.07
20.99
-9.15
Helicos Biosciences
HLCS
10.50
12.50
-16.00
Illumina
ILMN
72.41
63.70
13.67
Invitrogen
IVGN
84.49
85.67
-1.38
Lumera
LMRA
2.40
2.67
-10.11
Luminex
LMNX
17.41
14.97
16.30
MDS
MDZ
16.73
16.94
-1.24
Millipore
MIL
69.90
70.15
-0.36
Nanogen
NGEN
0.60
0.41
46.34
Nanosphere
NSPH
9.25
12.02
-23.04
Orchid Cellmark
ORCH
4.59
4.97
-7.65
PerkinElmer
PKI
24.82
24.82
0.00
Qiagen
QGEN
21.99
20.40
7.79
Rosetta Genomics
ROSG
4.86
5.29
-8.13
Sequenom
SQNM
6.99
8.29
-15.68
Sigma-Aldrich
SIAL
55.02
49.66
10.79
Thermo
TMO
55.93
51.49
8.62
Third Wave
TWTI
7.97
8.14
-2.09
Vermillion
VRML
0.53
0.60
-11.67
Waters
WAT
59.61
57.30
4.03
GWDN Index Average 27.41
26.96
1.68

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.